DDInter255 DDInter281
Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. Both heavy chains of canakinumab contain oligosaccharide chains linked to the protein backbone at asparagine 298 (Asn 298). Canakinumab binds to human IL-1β and neutralizes its inflammatory activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1alpha or IL-1 receptor antagonist (IL-1ra). Canakinumab is marketed under the brand name Ilaris and indicated for patients 4 years of age and older to treat Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), which are both part of the Cryopyrin-Associated Periodic Syndromes (CAPS) as well as for patients 2 years of age and older to treat systemic juvenile idiopathic arthritis (SJIA). Clinical trials have established the administration of canakinumab every 2 weeks to be safe and effective, offering a considerable advantage over the existing treatment with the human IL-1 receptor antagonist, anakinra, which must be injected daily and which is often poorly tolerated by patients.
Busulfan {u} (Compound) binds {v} (Gene) GSTA2
GSTA2 {u} (Gene) is bound by {v} (Compound) Vitamin E
Vitamin E {u} may cause a minor interaction that can limit clinical effects when taken with {v} Canakinumab
Busulfan {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Alprazolam
Alprazolam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Canakinumab
Busulfan {u} (Compound) downregulates {v} (Gene) STXBP1
STXBP1 {u} (Gene) is upregulated by {v} (Compound) Alprazolam
Alprazolam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Canakinumab
Busulfan {u} (Compound) downregulates {v} (Gene) TSPAN4
TSPAN4 {u} (Gene) is downregulated by {v} (Compound) Alprazolam
Alprazolam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Canakinumab
Busulfan {u} (Compound) downregulates {v} (Gene) STXBP1
STXBP1 {u} (Gene) is upregulated by {v} (Compound) Bosutinib
Bosutinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Canakinumab
Busulfan {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Apixaban
Apixaban {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Canakinumab
Busulfan {u} (Compound) downregulates {v} (Gene) TSPAN4
TSPAN4 {u} (Gene) is downregulated by {v} (Compound) Ponatinib
Ponatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Canakinumab
Busulfan {u} (Compound) causes {v} (Side Effect) Dizziness
Dizziness {u} (Side Effect) is caused by {v} (Compound) Alprazolam
Alprazolam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Canakinumab
Busulfan {u} (Compound) causes {v} (Side Effect) Angiopathy
Angiopathy {u} (Side Effect) is caused by {v} (Compound) Apixaban
Apixaban {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Canakinumab
Busulfan {u} (Compound) downregulates {v} (Gene) GDF15
GDF15 {u} (Gene) is downregulated by {v} (Compound) Leflunomide
Leflunomide {u} may lead to a major life threatening interaction when taken with {v} Canakinumab
Busulfan (Compound) binds GSTA2 (Gene) and GSTA2 (Gene) is bound by Vitamin E (Compound) and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Canakinumab
Busulfan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Alprazolam (Compound) and Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab
Busulfan (Compound) downregulates STXBP1 (Gene) and STXBP1 (Gene) is upregulated by Alprazolam (Compound) and Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab
Busulfan (Compound) downregulates TSPAN4 (Gene) and TSPAN4 (Gene) is downregulated by Alprazolam (Compound) and Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab
Busulfan (Compound) downregulates STXBP1 (Gene) and STXBP1 (Gene) is upregulated by Bosutinib (Compound) and Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab
Busulfan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Apixaban (Compound) and Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab
Busulfan (Compound) downregulates TSPAN4 (Gene) and TSPAN4 (Gene) is downregulated by Ponatinib (Compound) and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab
Busulfan (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Alprazolam (Compound) and Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab
Busulfan (Compound) causes Angiopathy (Side Effect) and Angiopathy (Side Effect) is caused by Apixaban (Compound) and Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab
Busulfan (Compound) downregulates GDF15 (Gene) and GDF15 (Gene) is downregulated by Leflunomide (Compound) and Leflunomide may lead to a major life threatening interaction when taken with Canakinumab